A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus

BACKGROUND AND PURPOSE: In 2017, eculizumab has been approved for treatment-refractory generalised myasthenia gravis (TRgMG). The German Myasthenia Foundation has published a consensus statement on the use of eculizumab, with a recent update. However, a treatment-refractory state is still ill-define...

Descripción completa

Detalles Bibliográficos
Autores principales: Schroeter, Michael, Berger, Benjamin, Blaes, Franz, Hagenacker, Tim, Jander, Sebastian, Kaiser, Julia, Kalischewski, Petra, Lee, De-Hyung, Ruck, Tobias, Schara, Ulrike, Urban, Peter, Meisel, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863150/
https://www.ncbi.nlm.nih.gov/pubmed/33597816
http://dx.doi.org/10.1177/1179573521989151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863150/
https://www.ncbi.nlm.nih.gov/pubmed/33597816
http://dx.doi.org/10.1177/1179573521989151

Ejemplares similares